ATE550023T1 - Stabile feste zubereitung mit 4,5- epoxymorphinanderivat - Google Patents

Stabile feste zubereitung mit 4,5- epoxymorphinanderivat

Info

Publication number
ATE550023T1
ATE550023T1 AT08752145T AT08752145T ATE550023T1 AT E550023 T1 ATE550023 T1 AT E550023T1 AT 08752145 T AT08752145 T AT 08752145T AT 08752145 T AT08752145 T AT 08752145T AT E550023 T1 ATE550023 T1 AT E550023T1
Authority
AT
Austria
Prior art keywords
solid preparation
stable solid
derivative
epoxymorphinand
effective ingredient
Prior art date
Application number
AT08752145T
Other languages
English (en)
Inventor
Suguru Takaki
Kotoe Ohta
Yasuhide Horiuchi
Masato Kobayashi
Junko Kawasaki
Eijiro Horisawa
Original Assignee
Toray Industries
Maruho Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Maruho Kk filed Critical Toray Industries
Application granted granted Critical
Publication of ATE550023T1 publication Critical patent/ATE550023T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Epoxy Resins (AREA)
AT08752145T 2007-04-26 2008-04-25 Stabile feste zubereitung mit 4,5- epoxymorphinanderivat ATE550023T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007116721 2007-04-26
PCT/JP2008/058111 WO2008133330A1 (ja) 2007-04-26 2008-04-25 4,5-エポキシモルヒナン誘導体を含有する安定な固形製剤

Publications (1)

Publication Number Publication Date
ATE550023T1 true ATE550023T1 (de) 2012-04-15

Family

ID=39925776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08752145T ATE550023T1 (de) 2007-04-26 2008-04-25 Stabile feste zubereitung mit 4,5- epoxymorphinanderivat

Country Status (14)

Country Link
US (1) US8420662B2 (de)
EP (1) EP2151241B1 (de)
JP (2) JP5099127B2 (de)
KR (1) KR101491656B1 (de)
CN (1) CN101686976B (de)
AT (1) ATE550023T1 (de)
AU (1) AU2008244936B2 (de)
CA (1) CA2685131C (de)
DK (1) DK2151241T3 (de)
ES (1) ES2381056T3 (de)
MX (1) MX2009011554A (de)
PL (1) PL2151241T3 (de)
PT (1) PT2151241E (de)
WO (1) WO2008133330A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
EP2630150B1 (de) * 2010-10-19 2017-04-12 Memorial Sloan-Kettering Cancer Center 6-amido-derivat aus 4,5-a-epoxymorphinanen zur schmerzbehandlung
JP2013087170A (ja) * 2011-10-17 2013-05-13 Nippon Soda Co Ltd ヒドロキシプロピルセルロース微粒子
ES2903149T3 (es) 2012-05-14 2022-03-31 Shionogi & Co Preparación que contiene derivado de 7-carbamoilmorfinano 6,7-insaturado
GB201318394D0 (en) * 2013-10-17 2013-12-04 Univ Edinburgh Composition
EP4212532A3 (de) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynin-analoga und verwendungen davon
CN105461727A (zh) * 2015-12-01 2016-04-06 吕涛 一种纳呋拉啡的精制方法
US11185509B2 (en) 2016-07-29 2021-11-30 Toray Industries, Inc. Solid preparation having improved light stability
ES2902123T3 (es) 2017-03-31 2022-03-25 Toray Industries Composición medicinal en tabletas que comprende nalfurafina
HUE069820T2 (hu) 2018-03-08 2025-04-28 Victoria Link Ltd Nalfurafin alkalmazása demielinizációs betegségek kezelésére
US11214577B2 (en) 2019-03-29 2022-01-04 Humanwell Pharmaceutical US Morphinans useful for treating medical disorders
JP7728367B2 (ja) 2021-06-14 2025-08-22 スコーピオン・セラピューティクス・インコーポレイテッド がんを処置するために使用され得る尿素誘導体
EP4212149A1 (de) * 2022-01-18 2023-07-19 Rijksuniversiteit Groningen Orale dosierungsformen von säurelabilen salzen und verfahren und verwendung davon

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
ES2121988T3 (es) 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
NZ331001A (en) 1996-11-25 2000-05-26 Toray Industries Use of an opiate K receptor agonist as an antipruritic
ES2141631T3 (es) 1997-02-14 2000-03-16 Goedecke Ag Estabilizacion del hidrocloruro de naloxon.
JP4939680B2 (ja) 1997-05-27 2012-05-30 武田薬品工業株式会社 固形製剤
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
ATE268178T1 (de) * 1997-07-11 2004-06-15 Toray Industries Stabile medizinische zusammenstellungen die 4,5- epoxymorphinanderivate enthalten
US6524568B2 (en) * 1998-06-22 2003-02-25 Cytomedix, Inc. Enriched platelet wound healant
EP1133984B1 (de) 2000-03-17 2005-05-11 Shin-Etsu Chemical Co., Ltd. Feste Zubereitung enthaltend niedersubstituierte Hydroxypropylcellulose und Herstellungsverfahren
JP3698652B2 (ja) 2000-03-17 2005-09-21 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース含有固形製剤及びその製造方法
WO2001076565A1 (fr) 2000-04-12 2001-10-18 Banyu Pharmaceutical Co., Ltd. Compositions et preparations se desintegrant dans la cavite buccale
JP3595765B2 (ja) * 2000-09-27 2004-12-02 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロースを含む乾式直打用基剤
AU2002238848B2 (en) 2001-03-06 2007-11-15 Kyowa Hakko Kogyo Co., Ltd. Use of a spray-dried powder comprising a sugar alcohol
JP4683842B2 (ja) 2002-03-14 2011-05-18 ユーロ−セルティーク エス.エイ. 塩酸ナルトレキソン組成物
TWI286942B (en) * 2002-06-10 2007-09-21 Dainippon Sumitomo Pharma Co Rapidly disintegrating tablet and preparing method thereof
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona

Also Published As

Publication number Publication date
EP2151241A1 (de) 2010-02-10
WO2008133330A1 (ja) 2008-11-06
EP2151241A4 (de) 2010-06-02
CA2685131A1 (en) 2008-11-06
CA2685131C (en) 2015-05-19
US20100120815A1 (en) 2010-05-13
EP2151241B1 (de) 2012-03-21
JP5578199B2 (ja) 2014-08-27
AU2008244936A1 (en) 2008-11-06
PT2151241E (pt) 2012-05-07
US8420662B2 (en) 2013-04-16
DK2151241T3 (da) 2012-04-23
JP2012180382A (ja) 2012-09-20
ES2381056T3 (es) 2012-05-22
AU2008244936B2 (en) 2013-02-21
PL2151241T3 (pl) 2012-08-31
JPWO2008133330A1 (ja) 2010-07-29
KR101491656B1 (ko) 2015-02-09
JP5099127B2 (ja) 2012-12-12
MX2009011554A (es) 2010-01-25
KR20100015582A (ko) 2010-02-12
CN101686976B (zh) 2013-04-24
CN101686976A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
ATE550023T1 (de) Stabile feste zubereitung mit 4,5- epoxymorphinanderivat
MA32604B1 (fr) Composes organiques
EA200900044A1 (ru) Замещенные производные 1,3-дифенилпропана, получение и их применение
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
UY28797A1 (es) 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparación y el uso de las mismas para combatir hongos nocivos, así como productos que las contienen.
CO6280584A2 (es) Derivados heterociclicos fungicidas de (tetrazolil-benzilideneamido)-oximetil
MX2011011175A (es) Coposiciones herbicidas de alta concentracion de las sales de glifosato y de 2,4-d.
ECSP088307A (es) Derivados fungicidas de fenilamidina sustituida con piridiniloxi
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
MY151295A (en) Pyrimidyl indoline compound
JP2015514120A5 (de)
FI3817751T3 (fi) Vedettömän natriumtiosulfaatin formulaatioita
EA201300715A1 (ru) Бульонный кубик
BRPI0922701A8 (pt) Método para intensificar atividade viral mediada por interferon em um animal de companhia
GT201400027A (es) Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
CO6351744A2 (es) Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridini-3-il]-2-metil-4´-(trifluoro-metoxi)-[1,1´-bifenil]-3-carboxamida
TN2010000585A1 (en) Pharmaceutical compositions of rosuvastatin calcium
CY1116266T1 (el) Σταθερα αλατα της s-αδενοσυλμεθειονινης και μεθοδος παρασκευης τους
UY29416A1 (es) Derivados de ácido pirimidincarboxílico y su uso
EP2152292A4 (de) Angiogenese-hemmer mit meteorin als wirkstoff
PE20080149A1 (es) Formulacion liquida acuosa que comprende un beta bloqueador